Your Guide to Peptide Research

A small molecule NNMT inhibitor studied for metabolic enhancement and fat cell reduction.

Abaloparatide (Tymlos) is a synthetic 34-amino-acid analog of parathyroid hormone-related protein, PTHrP(1-34), engineered to bind the PTH1 receptor with a strong preference for its transient RG conformation rather than the long-lived R0 conformation favored by teriparatide. That receptor bias produces a shorter burst of signaling per injection - enough to drive osteoblast activity, but short enough to limit the bone resorption and calcium mobilization that follow a prolonged signal. In the 18-month Phase 3 ACTIVE trial in 2,463 postmenopausal women, abaloparatide 80 mcg daily reduced new morphometric vertebral fractures by 86% versus placebo, alongside significant reductions in nonvertebral, major osteoporotic and clinical fractures. The FDA approved Tymlos in April 2017; in December 2021 the osteosarcoma boxed warning and the two-year cumulative lifetime limit were both removed from the label.

An oral, once-daily small-molecule amylin receptor agonist in first-in-human Phase 1 testing for obesity — an early entrant in the race to make amylin biology available as a pill rather than an injection.

A new class of antimicrobial peptides discovered and optimized using artificial intelligence platforms, with over 79 active compounds identified from a catalog of 863,498 AI-predicted sequences showing efficacy against multidrug-resistant pathogens.

An oral non-peptide small-molecule GLP-1 receptor agonist achieving 16.3% placebo-adjusted weight loss at 44 weeks in Phase 2 ACCESS II, with Phase 3 on track for Q3 2026 after positive FDA end-of-Phase 2 feedback.

A bifunctional GIPR-antagonist / GLP-1 receptor-agonist peptide in early clinical development for obesity, designed to improve the quality and durability of weight loss and long-term weight maintenance.

Sebetralstat is the first pill that can stop a hereditary angioedema attack on demand. An oral plasma kallikrein inhibitor, it cut the median time to symptom relief to under two hours versus nearly seven on placebo - and in 2026 it posted positive pediatric data and a first-line guideline nod. Here is how it works, what KONFIDENT showed, and how it fits the HAE toolkit.

Garadacimab is the first HAE prevention drug to switch off the swelling cascade at its very first step. A once-monthly antibody against activated Factor XII, it cut monthly attacks by ~89% versus placebo and left 62% of patients attack-free - and in July 2026 it posted positive results in children. Here is how it works, what the data show, and how it compares to the rest of the HAE toolkit.

Atacicept spent two decades looking for the right disease - it failed in multiple sclerosis and stumbled in lupus. In IgA nephropathy it finally found its footing: on July 7, 2026 the FDA approved it as Trutakna, the first dual BAFF/APRIL inhibitor for the disease, after a Phase 3 trial cut proteinuria 42% versus placebo. Here's how it works, what the data show, and the accelerated-approval asterisk.